Twist Bioscience Corporation (Nasdaq: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Vivlion GmbH, a company providing next-generation CRISPR gRNA libraries and screening services for the global R&D market, today announced a collaboration for the generation of gRNA libraries for CRISPR applications. CRISPR\Cas is a powerful functional genomics tool used for a wide range of applications including genome engineering and target discovery for drug development.
“Research using CRISPR continues to accelerate into many different areas. This collaboration combines Twist’s ability to generate highly uniform long oligos at scale with Vivlion’s ability to translate these into equally highly uniform CRISPR libraries for the next generation of high-throughput CRISPR screenings,” said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience.
Per this collaboration, Vivlion will purchase Twist Oligo Pools to generate and sell precision CRISPR libraries for functional genomics research. Vivlion’s proprietary 3Cs technology bypasses standard cloning methods such as PCR amplification, allowing direct conversion of Twist’s high-quality Oligo Pools into gRNA libraries that maintain Twist’s unrivaled uniformity, including the generation of multiplexed and fixed-pair libraries.
“Twist is the ideal partner for the oligos needed for our CRISPR libraries. Their market expertise and ability to quickly generate large quantities of long, high-quality oligonucleotides provides Vivlion with a ready-made platform to amplify our impact,” said Ivan Đikić, CEO of Vivlion. “The combined technologies have the potential to accelerate genomic research and enable scientists to decipher the function of genes more quickly.”
For more such updates and perspectives around Digital Innovation, IoT, Data Infrastructure, AI & Cybsercurity, go to AI-Techpark.com.
